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SUMMARY
Serum- and/or- cerebrospinal fluid (CSF) samples obtained from 190 patients suffering from chronic, progressive neurological
disease were screened for the presence of human T-cell lymphotropic viruses type I (HTLV-I) and type II (HTLV-II) antibodies over
a six-year period (1996 to 2001) in Belém, Pará, Brazil. Patients were of both sexes (male subjects, 52%) with ages ranging from 2 to
79 years (mean, 35.9). Overall, 15 (7.9%) subjects - of whom 12 (80%) were female adults - reacted HTLV-I/II-seropositive when
screened by enzyme-linked immunosorbent assay (ELISA). Serum samples from 14 of these patients were also analyzed using a
recombinant Western blot (WB) assay that yielded HTLV-I-, HTLV-II-, and HTLV-I/II- reactivities for 10 (71.4%), 3 (21.4%) and 1
(7.2%) of them, respectively. The yearly rates of HTLV-I/II antibodies ranged from 2.6% (2001) to 21.7% (2000), with progressively
increasing seropositivities from 1998 to 2000. Altogether, walking difficulty (n = 5 subjects), spasticity (n = 4) and leg weakness (n
= 3) accounted for 80% of symptoms recorded among the 15 patients whose sera had antibodies to HTLV-I/II as detected by ELISA.
These findings provide evidence that both HTLV-I and HTLV-II play a role in the development of chronic myelopathy in Belém, Pará,
Northern Brazil.
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INTRODUCTION
Although primarily recognized as playing a role in the etiology of
adult T-cell leukemia (ATL)28, the human T cell lymphotropic virus type I
(HTLV-I) is currently known to be associated with a variety of clinical
conditions in humans. In fact, the broad spectrum of disease manifestations
associated with HTLV-I infection also includes HTLV-I associated
myelopathy/tropical spastic paraparesis (HAM/TSP)10,27, uveitis22, chronic
inflammatory arthropathy24, polymyositis23, Sjögren‘s syndrome20,
infective dermatitis of children17, and facial nerve palsy4. Human T cell
lymphotropic virus type II (HTLV-II), in its turn, appears not having
absolute association with any human disease to date, even though evidence
is currently growing in that it might be etiologically linked to chronic,
progressively neurological syndromes, including HAM/TSP6,11.
Worldwide, the association between HTLV-I and HAM/TSP has been
demonstrated in southwestern Japan, the West Indies, the Seychelle
Islands, Africa, and South America11,19. Transmission of HTLV-I may
occur via sexual contact, breast milk and transfusion of blood products;
this latter mode of HTLV transmission has been associated with an
increased risk for developing HAM/TSP16,26.
During the past few years a number of studies in Brazil have dealt
with the association between HTLV (mostly HTLV-I) and chronic
neurodegenerative disorders. Data from early studies conducted in North
Brazil have postulated the relationship between HTLV-I infection and
the development of Guillain-Barré syndrome in a 12 year-old boy25. The
nationwide occurrence of HTLV-I infection in patients with HAM/TSP
has been documented by several studies showing that both sexual
promiscuity and blood transfusion appear to be the most important risk
factors for transmission, with prevalence rates being higher among female
subjects1,2,3,7,8,9,31. A pilot study conducted in Belém, Northern Brazil
yielded a 9% prevalence rate of HTLV-I/II infection in a cohort of 144
patients presenting with clinical symptoms of myelopathy18. Also in
Belém, Pará, Brazil, HTLV-I-associated myelopathy has been reported
recently in three patients12. In addition to studies carried out in Amazonian
urban communities, a possible case of HAM/TSP has been diagnosed in
a remote Indian village where endemic transmission of HTLV-II is known
to occur5,6.
Herein we present data from a survey of the prevalence of HTLV-I
and HTLV-II infections among patients suffering from neurological
diseases of unknown etiology.
MATERIAL AND METHODS
Patients: Our study cohort comprised 190 outpatients of both sexes
(male subjects, 77) living in Belém, Northern Brazil - with ages ranging
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from 2 to 79 years – who were referred by local neurologists to the
Virology Section of Instituto Evandro Chagas, over a period of six years
(1996 to 2001). Overall, referred patients presented with one or more
symptoms and signs gathered in the “HTLV-I-associated neurological
complex”, as described by MARSH21, where HAM/TSP appears as the
most common clinical condition. A serological screening for HTLV
infection was invariably requested for these subjects by the referring
neurologists.
Samples and serological assays: Between 5 and 10 ml of blood
was obtained from each of the 190 patients using tubes without
anticoagulant; sera was further separated from each sample and kept
frozen at -20 °C until processing. In addition, cerebrospinal fluid samples
(CSFs) (3 - 5 ml each) were available from 21 subjects. Sera (and CSFs,
when available) were initially screened for the presence of HTLV
antibodies using a three-stage enzyme-linked immunosorbent assay
(ELISA) that utilizes microwells coated with recombinant HTLV-I and
HTLV-II antigens (Ortho, Raritan, NJ, USA). All specimens reacting
positive in the initial screening were, thereafter, retested in duplicate by
ELISA. Repeatedly reactive samples were further confirmed using a
newly developed Western-blot assay (WB)34 that includes either
recombinant proteins or synthetic peptides highly purified and fixed onto
a nylon membrane (INNO-LIATM HTLV I/II, Immunogenetics N.V.,
Ghent, Belgium). As based on test principle described by manufacturers,
bands corresponding to two core proteins encoded by gag gene (p19 I/II
and p24 I/II) and env gene glycoprotrein products gp46 I/II (external
envelope) and gp21 I/II (small transmembrane) are applied as non-type-
specific antigens, to ensure that antibodies against HTLV I/II are present.
Recombinant proteins/synthetic peptides applied to define type-
specificities are gag p19-I and env gp46-I (HTLV-I) and env gp46-II
(HTLV-II). This system allows for classification of positive samples as
HTLV-I, HTLV-II, mixed HTLV-I/II or untypeable.
In an attempt to rule out aetiologies other than HTLV-I/II infection,
serum samples from 11 of the 15 HTLV I/II-seropositive patients were
tested for hepatitis C virus (HCV) antibodies by using a third-generation
ELISA which includes antigens from the NS5 region (Ortho-Clinical
Diagnostics, Inc., Raritan, NJ, USA). In addition to this, available medical
documentation provided information on hematological values and serum
glucose levels.
Statistical analysis: This was done with EPI-INFO software, version
6.0 (Atlanta, GA, USA). Comparison of rates between groups were made
with the Mantel-Haenszel chi-square test of association or, if assumptions
required for the chi-square test were not met, with Fisher’s exact test.
Significance was defined as p < 0.05.
RESULTS
The general characteristics, clinical symptoms and laboratory
findings for 15 HTLV I/II-seropositive patients are presented in Table 1,
covering the period between May 1996 and December 2001. While serum
samples were available for all 15 subjects, a CSF sample could be obtained
from patient no. “1” only, also reacting HTLV-I-positive. Ages at
presentation ranged from 21 years to 79 years, with female patients
accounting for 80% of HTLV-reactive subjects. Taken together, walking
difficulty (n = 5 subjects), spasticity (n = 4) and leg weakness (n = 3)
were recorded in 80% of HTLV-seropositive patients, with reported
disease duration varying from one month to 12 years. While HTLV-II-
positive subjects had either leg myalgia, walking difficulty or spasticity,
the only HTLV-I/II-positive patient developed paraplegia. Figure 1
displays Western blot profiles of a representative number of HTLV-
seropositive patients (lanes A through I), of whom (a) six (A, B, C, D, G
and H) were HTLV-I reactive, (b) two (E and I) had HTLV-II antibodies,
and (c) one (F) yielded a pattern compatible with a dual, concurrent
Table 1
General characteristics, symptoms and laboratory findings for 15 HTLV I/II-positive patients with neurological diseases in Belém, Brazil
Patient Age Sex Main symptoms  or diagnosis Duration of Month, year of HTLV- Typing
no.  (years)  illness*  blood sampling
1  62  F  Leg weakness and peripheral sensory loss  2 years  May, 1996**  I
2  21  F  Leg weakness/trembling and walking difficulty  2 years  December, 1996  I
3  45  F  Hypotonia, leg myalgia and walking difficulty  1 year  April, 1997  I
4  55  F  Spastic paraparesis  ?  November, 1997  I
5  23  F  Spastic paraparesis and paresthesia  3 years  August, 1998  I
6***  ?  M  Occasional abrupt vertigo  “A few months”  February, 1999  I
7  58  F  Leg weakness and vertigo  3 years  September, 1999  I
8  66  M  Leg hypotonia and spasticity of extremities  12 years  November, 1999  II
9  43  F  Walking difficulty and lower limbs paresthesia  3 years  April, 2000  I
10  61  F  Paraplegia  12 years  April, 2000  I + II
11  24  F  Walking difficulty  2 years  June, 2000  I
12  46  F  Lower limbs paraparesis  1 year  ?  I
13  79  M  Walking difficulty  1 month  ?  II
14  33  F  Leg myalgia  1 month  April, 2001  II
15  57  F  Spastic paraparesis and walking difficulty  5 years  December, 2001  NT
*, Approximate duration of symptoms, as reported by the patient; **, HTLV-I-reactive CSF obtained from this patient on June, 1996; ***, a probable HTLV-related
case; and ?, Information not available
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HTLV-I and HTLV-II infection. The annual distribution of patients
according to their HTLV antibody reactions is presented in Fig. 2. Overall,
seropositivity rates ranged from 2.6% to 21.7% for years 2001 and 2000,
respectively. The rates of HTLV-seropositivity tended to be higher (p =
0.15) during the biennium 1999-2000 than for the three previous years
combined; the percent HTLV-reactivity in 2001 was significantly lower
(p = 0.009) than during the rest of the six-year study period. While HTLV-
I-reactive subjects were identified throughout the first five consecutive
years (1996 to 2000), HTLV-II infections were limited to the period of
1999 to 2001.
Sera from the eleven HTLV-I/II-seropositive patients who were tested
for the presence of HCV antibodies yielded negative results and no
evidence was apparent suggesting the occurrence of either diabetes
mellitus or B12 and/or folate deficiencies.
DISCUSSION
Data from the present study provide evidence that HTLV-related
neurological disorders in Belém, Northern Brazil appear to be of emerging
public health importance12,18,25. The overall 8% seropositivity rate in our
investigation is similar to that recorded in a previous, pilot local survey18
where 9% of screened patients suffering from neurological disease were
found to have HTLV-I/II antibodies. The seropositivity rate in our study
tended to be lower, however, if compared with those rates from other
surveys conducted across Brazil, which varied from 14.7% to 57%1,2,8.
A possible explanation for this difference is the fact that our study cohort
comprised patients whose sera were tested for the presence of HTLV-I/
II antibodies primarily at the request of the referring local neurologists.
Moreover, all referred individuals were found to present with at least
one symptom or sign which would be required to assign them to the
“HTLV-I-associated neurological complex”, as defined by MARSH21.
Of note, since age could not be retrieved for “Patient no. 6” (Table I),
one cannot rule out a possible relationship between vertigo and clinical
conditions other than those of the “HTLV-I-associated neurological
complex”21 such as dyslipidemia, degeneration of the spinal cord and
vertebrobasilar insufficiency. Contrasting with this wide spectrum of
neurological clinical conditions, the other studies under comparison have
in general adopted a more strict criteria for inclusion of patients, namely
the World Health Organization classic definition for HAM/TSP19,29. This
definition includes mainly a chronic myelopathy diagnosis, as defined
by the occurrence of a motor deficit with pyramidal pattern in association
with autonomic involvement for at least five months.
Despite the broad age-range of patients referred for HTLV-I/II
antibody screening, it is noticeable that only adults of both sexes (mean
age, 48 years) were found to be reactive by both ELISA and WB. These
findings are consistent with the general concept that the average age of
diagnosis is 40 years, with infection being most commonly acquired
during adulthood19. Our data showing that female patients accounted
for 80% of HTLV-I/II seropositive results are also compatible with
previous observations indicating that HAM/TSP is more common in
women than men at all age groups. It should be pointed out in this regard
that previous studies have suggested that such a gender difference usually
becomes more evident after the age of 30 years, probably reflecting a
more efficient transmission of HTLV-I from males to females during
sexual intercourse11,19.
The trend toward higher reactivity rates during 1999-2000, as
compared with previous years of observation, suggests that local
neurologists became increasingly more aware as to the importance of
screening patients with chronic myelopathies for HTLV-I/II antibodies.
Intriguingly, however, is the fact that only 2.6% of patients were
seropositive in 2001. Since the utilized laboratory methods did not change
throughout the whole study period and age-groups were evenly
distributed across the years (data not shown in table), it seems likely that
such unexpected low seropositivity rate may have occurred by chance,
owing to the general, relatively low number of study subjects. An
alternative, though apparently paradoxical explanation, is that once fully
aware of the laboratory facilities for diagnosis, clinicians were perhaps
less strict when selecting patients for HTLV-I/II serological screening.
Whatever explanation should be for this latest downward shift in
seropositivity, more representative data on the epidemiology of HAM/
TSP in our region would only be achievable through the conduct of
Fig. 1 - Western immunoblot for antibodies to polypeptides of humanT lymphotropic viruses
types I and II. Patients A, B, C, D, G and H are HTLV-I seropositive; patients E and I are
HTLV-II seropositive; and, patient F is HTLV-I/II reactive. (+) and (-) denote HTLV-reactive
and HTLV-non-reactive test controls, respectively.
Fig. 2 - Annual distribution of tested patients according to HTLV antibody status in Belém,
Brazil.
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further studies that might gather a number of patients much larger than
reported either herein or elsewhere12,18.
Although all patients referred by local neurologists have met the
clinical criteria required for their inclusion in the “HTLV-I-associated
neurological complex”, it is noticeable that 14 of the 15 individuals who
reacted HTLV-I/II-positive presented with at least one neurological/motor
disorder which were compatible with the WHO definition criteria for
HAM/TSP29. The fact that almost 90% of our patients reacted seronegative
underscores the need for a routine differential diagnosis of HTLV-I/II-
related neurological disorders with a variety of other clinical conditions
which might be gathered in the context of either acute or chronic
myelopathies30. In tropical regions like ours, parasitic diseases including
toxoplasmosis, schistosomiasis and cysticercosis, for example, cannot
be ruled out when seeking for the etiology of neurological disorders that
might resemble some of those of HAM/TSP. Also in these settings, B12
and folate deficiencies may lead to neurological disorders that would
mimic those found in HTLV-I/II-related diseases. It should be pointed
out in this context, however, that sera from all 15 HTLV-reactive patients
were negative when tested for hepatitis C antibodies by conventional
enzyme immunoassays; in addition, as based on available medical
documentation from these patients, there was no indication that they
were suffering from diabetes mellitus or B12/folate deficiencies.
A major finding in our study was the occurrence of HTLV-II-related
neurological disease in three patients, including one case in which a dual
HTLV-I- and- HTLV-II infection could be diagnosed. To our knowledge,
these findings seem to be the first in the Amazon region providing
serological evidence that HTLV-II infection may be associated with HAM/
TSP in urban settings. Of note, BLACK et al.6 have described a possible
case of TSP in a HTLV-II-seropositive, 40-year old Indian woman who
lived in the Kayapo village in the Southeastern Amazon basin, Pará state,
Brazil. Of importance in this context, several reports have demonstrated
the endemic transmission of HTLV-II (subtypes a and c) among the Kayapo
Indians of Brazil, a remote community where mother-to-child transmission
(mainly via breast-feeding) appear to be especially important5,13,15,32.
Additional reports have focussed on the occurrence of HTLV-II infection
in selected urban populations of Belém, Brazil, namely blood donors and
HIV-1 infected patients, albeit no neurological disturbances have been
identified so far14,33. It is noteworthy in our study cohort the fact that HTLV-
II-infected patients were identified as from 1999 onwards, and a relatively
short duration of their illnesses (one month) has been reported. These
findings give rise to the hypothesis of possible recent introduction of HTLV-
II in urban settings in our region, an issue that should be taken into account
when further assessing the growing public health concern as to the
countrywide HTLV-I/II-related disease burden. In light of such a
hypothesis, it would seem also plausible to postulate that our 61-year old
paraplegic female patient with serological evidence of dual (HTLV-I and
HTLV-II) infection might have been infected primarily by HTLV-I, with a
subsequent, perhaps recent infection by HTLV-II.
Although serological and clinical data presented herein are strongly
suggestive that a relationship exists between HTLV-I/II infection and
neurological diseases in our region, it is noticeable that our study had
two limitations. First, cerebrospinal fluids (CSFs) were not available
from most of local patients, preventing us from having a more direct
evidence of central nervous system involvement through the detection
of specific antibodies in these samples. In fact, among the 15 HTLV-
positive subjects, a CSF sample could be obtained from one patient only,
yielding the same HTLV-typing specificity as detected in serum. Of note,
all of the remainder 20 CSF samples from HTLV-negative patients also
yielded negative results. Secondly, since patients were referred primarily
with the purpose of laboratory diagnosis only, data on risk factors for
HTLV-I/II infection were lacking, making it difficult to trace a possible
source of virus transmission among affected individuals.
A clearer understanding on the epidemiological features of HAM/
TSP in our region is needed. In order to achieve this goal, however,
comprehensive further studies should be conducted including a more
extensive screening of patients for HTLV-I/II antibodies in their sera and
(whenever possible) CFS samples. By the way, like in other endemic regions
for HTLV-I infection, additional features such as susceptibility and rapid/
low disease progression are worth of exploring further11. It is also worth
in this regard to strengthen the awareness of local neurologists and clinicians
as to the public health importance of seeking for a laboratory diagnosis
whenever symptoms may suggest the occurrence of HAM/TSP. Finally,
monitoring of HTLV-I and HTLV-II circulating strains/subtypes should
be encouraged through the use of molecular biology techniques.
RESUMO
Infecção pelos vírus linfotrópicos humanos de células T tipos I e II
entre pacientes com doença neurológica em Belém, Pará, Brasil
Amostras de soro e/ou líquido céfalo-raquidiano (LCR) foram obtidas
de 190 pacientes com quadro de doença neurológica crônica e progressiva,
com vistas à detecção de anticorpos para os vírus linfotrópicos humanos
de células T dos tipos I (HTLV-I) e II (HTLV-II), durante um período de
seis anos (1996 a 2001) em Belém, Pará, Brasil. O grupo compreendia
ambos os sexos (homens, 52%), com idades variando de 2 a 79 anos (média,
35,9 anos). Tomando-se os resultados como um todo, 15 (7,9%) indivíduos,
incluindo 12 (80%) mulheres adultas, apresentaram anticorpos para HTLV-
I/II a partir da triagem pelo procedimento imunoenzimático (ELISA). Soros
de 14 desses pacientes também foram testados utilizando-se procedimento
de Western blot (WB), alcançando-se freqüências de anticorpos para HTLV-
I, HTLV-II e dupla reação (HTLV-I e HTLV-II) em 10 (71,4%), 3 (21,4%)
e 1 (7,2%) indivíduos, respectivamente. As freqüências anuais de
positividade para HTLV-I/II variaram de 2,6% (2001) a 21,7% (2000), em
escala crescente no período de 1998 a 2000. Em conjunto, dificuldade na
deambulação (n = 5 pacientes), espasticidade (n = 4) e hipotonia crural
compreenderam 80% das manifestações clínicas registradas entre os 15
pacientes cujas amostras de soro continham anticorpos para HTLV-I/II,
com base em ELISA. Tais resultados oferecem indicadores quanto a uma
possível associação do HTLV-I e do HTLV-II à gênese das mielopatias
crônicas em Belém, norte do Brasil.
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